<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC89857</article-id><article-id pub-id-type="pmcid-ver">PMC89857.1</article-id><article-id pub-id-type="pmcaid">89857</article-id><article-id pub-id-type="pmcaiid">89857</article-id><article-id pub-id-type="pmid">10770764</article-id><article-id pub-id-type="doi">10.1128/aac.44.5.1291-1295.2000</article-id><article-id pub-id-type="publisher-id">0545</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Experimental Therapeutics</subject></subj-group></article-categories><title-group><article-title>Pharmacodynamic Assessment of Cefprozil against <italic>Streptococcus pneumoniae</italic>: Implications for Breakpoint Determinations</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Nicolau</surname><given-names initials="DP">David P.</given-names></name><xref ref-type="aff" rid="N0x97cd7f0.0x9e619f0">1</xref><xref ref-type="aff" rid="N0x97cd7f0.0x9e619f0">2</xref><xref ref-type="author-notes" rid="FN150">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Onyeji</surname><given-names initials="CO">Cyprian O.</given-names></name><xref ref-type="aff" rid="N0x97cd7f0.0x9e619f0">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhong</surname><given-names initials="M">Mingkang</given-names></name><xref ref-type="aff" rid="N0x97cd7f0.0x9e619f0">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tessier</surname><given-names initials="PR">Pamela R.</given-names></name><xref ref-type="aff" rid="N0x97cd7f0.0x9e619f0">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Banevicius</surname><given-names initials="MA">Mary Anne</given-names></name><xref ref-type="aff" rid="N0x97cd7f0.0x9e619f0">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nightingale</surname><given-names initials="CH">Charles H.</given-names></name><xref ref-type="aff" rid="N0x97cd7f0.0x9e619f0">3</xref></contrib></contrib-group><aff id="N0x97cd7f0.0x9e619f0"> Department of Pharmacy Research<sup>1</sup> and  Division of Infectious Diseases,<sup>2</sup> Office of Research Administration,<sup>3</sup> Hartford Hospital, Hartford, Connecticut 06102</aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: Division of Infectious Diseases, Hartford Hospital, 80 Seymour St., Hartford, CT 06102. Phone: (860) 545-3941. Fax: (860) 545-5112. E-mail: <email>dnicola@harthosp.org</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>5</month><year>2000</year></pub-date><volume>44</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">2484</issue-id><fpage>1291</fpage><lpage>1295</lpage><history><date date-type="received"><day>7</day><month>7</month><year>1999</year></date><date date-type="rev-request"><day>12</day><month>9</month><year>1999</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>22</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-10-31 10:56:17.363"><day>31</day><month>10</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac001291.pdf"/><abstract><p>Cefprozil, an oral semisynthetic cephalosporin, is commonly utilized in the treatment of respiratory-tract infections in children. While this agent has provided acceptable clinical success over a number of years, this study was undertaken to better define its pharmacodynamic profile against <italic>Streptococcus pneumoniae</italic>. Nineteen clinical isolates of <italic>S. pneumoniae</italic> were utilized in the neutropenic murine thigh infection model. To simulate the pharmacokinetic profile of cefprozil in children, the renal function of mice was impaired with uranyl nitrate, and a commercially available cefprozil suspension (6 mg/kg of body weight) was administered orally every 12 h. Mice were infected with 10<sup>6</sup> to 10<sup>7</sup> CFU per thigh, and therapy was initiated 2 h later. At 0 and 24 h postinfection, thighs were harvested to determine bacterial density. Survival was assessed during 96 h of therapy. The magnitude of bacterial kill ranged from 0.5 to 4.4 log<sub>10</sub> CFU per thigh over 24 h, and the extent of microbial eradication was dependent on the MIC. Killing of more than 2.6 log<sub>10</sub> CFU per thigh was observed with MICs of &#8804;3 &#956;g/ml, while either minimal killing or growth was detected with MICs of &#8805;4 &#956;g/ml. Mortality in untreated control animals was 100%. Animals infected with strains for which the MICs were &#8804;2 &#956;g/ml survived the infection, whereas MICs exceeding 2 &#956;g/ml resulted in substantial mortality. These studies demonstrate the effectiveness of cefprozil against isolates of the pneumococcus for which the MICs are &#8804;2 &#956;g/ml using a drug exposure typically observed in children. These data support a susceptibility breakpoint of &#8804;2 &#956;g/ml for cefprozil.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>